Cite

    Resnick, M. J., Barocas, D. A., Morgans, A. K., Phillips, S. E., Chen, V. W., Cooperberg, M. R., Goodman, M., Greenfield, S., Hamilton, A. S., Hoffman, K. E., Kaplan, S. H., Paddock, L. E., Stroup, A. M., Wu, X., Koyama, T., & Penson, D. F. (2014). contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer, 120(8), 1263–1271. http://access.bl.uk/ark:/81055/vdc_100070756305.0x000012